- Report
- March 2024
- 193 Pages
Global
From €3205EUR$3,374USD£2,757GBP
€3562EUR$3,749USD£3,064GBP
- Report
- April 2024
- 195 Pages
Global
From €1891EUR$1,990USD£1,626GBP
- Report
- January 2024
- 200 Pages
Global
From €4750EUR$5,000USD£4,086GBP
- Report
- April 2024
- 135 Pages
Global
From €3704EUR$3,899USD£3,186GBP
- Report
- May 2024
- 196 Pages
Global
From €5178EUR$5,450USD£4,454GBP
- Report
- April 2023
- 116 Pages
Global
From €4513EUR$4,750USD£3,882GBP
- Report
- February 2018
- 117 Pages
Global
From €4038EUR$4,250USD£3,473GBP
- Report
- May 2024
- 181 Pages
From €4655EUR$4,900USD£4,005GBP
- Report
- January 2022
- 120 Pages
Global
From €2375EUR$2,500USD£2,043GBP
- Report
- January 2021
- 148 Pages
China, Global
From €3000EUR$3,383USD£2,671GBP
- Report
- February 2024
- 92 Pages
Global
From €3500EUR$3,946USD£3,116GBP
- Report
- March 2024
- 132 Pages
Global
From €903EUR$950USD£776GBP
Antivenom is a type of vaccine used to treat venomous bites and stings. It is made from antibodies that are harvested from animals that have been immunized against the venom of a particular species. The antivenom is then injected into a person who has been bitten or stung by the venomous creature. The antibodies in the antivenom neutralize the venom, preventing it from causing further damage.
The antivenom market is a growing industry, with many companies producing and distributing antivenom products. These companies are typically focused on producing antivenom for specific species, such as snakes, spiders, and scorpions. The antivenom market is also expanding to include antivenom for other venomous creatures, such as jellyfish and sea snakes.
Some of the companies in the antivenom market include Sanofi Pasteur, GlaxoSmithKline, Merck, and CSL Limited. These companies produce antivenom products for a variety of species, and they are also involved in research and development of new antivenom products. Show Less Read more